Core Viewpoint - The company has received a drug registration certificate for its lyophilized human rabies vaccine (human diploid cells) from the National Medical Products Administration, marking a significant advancement in its vaccine product portfolio and competitive position in the rabies vaccine market [1][3]. Group 1: Drug Information - The drug is a lyophilized human rabies vaccine (human diploid cells) with an injection form, and each bottle contains 1.0ml, with a minimum potency of 2.5 IU per dose [1]. - The vaccine is classified as a preventive biological product and has been approved for domestic production, with a registration number valid until February 9, 2031 [1]. - Rabies is a highly fatal infectious disease with a near 100% mortality rate once symptoms appear, affecting approximately 60,000 people globally each year [1]. Group 2: Product Features and Competitive Advantage - The vaccine utilizes the MRC-5 human diploid cell line, recommended by the World Health Organization, ensuring excellent safety, immunogenicity, and durability, particularly for vulnerable populations such as the elderly and children [2]. - It is the first domestic human diploid cell rabies vaccine to include three immunization schedules: "simple 4-dose," "2-1-1," and "5-dose," enhancing adaptability for different exposure levels and patient compliance [2]. - The approval of the "simple 4-dose" immunization schedule represents a breakthrough in the adaptability of the vaccine, potentially increasing the completion rate of immunizations and optimizing post-exposure prevention strategies [2]. Group 3: Impact on the Company - The approval of the human diploid rabies vaccine will enhance the company's vaccine product layout, strengthen its core competitiveness, and solidify its market position in the rabies vaccine sector, providing new growth momentum for future development [3].

Core Viewpoint - The company Zhonghui Biotech-B (02627) has initiated Phase III clinical trials for its lyophilized rabies vaccine (human diploid cells) aimed at three immunization regimens, marking a significant step in its vaccine development process [1] Group 1: Clinical Trial Progress - The company received approval from the National Medical Products Administration of the People's Republic of China for new drug clinical trials for the Essen (five-dose) regimen in November 2022 [1] - In April 2023, the company obtained approval for supplementary clinical trial applications for the Zagreb (four-dose) and simplified four-dose regimens [1] - The company completed Phase I clinical trials for the rabies vaccine in October 2024 [1] Group 2: Vaccine Characteristics - Rabies is a severe viral disease caused by the rabies virus, leading to serious symptoms such as confusion and progressive paralysis, which are almost always fatal once symptoms appear [1] - Immediate vaccination after exposure to the virus can prevent rabies [1] - The rabies vaccine developed using human diploid cells is recognized as the "gold standard" rabies vaccine by the World Health Organization, demonstrating strong safety profiles [1] - The rabies vaccine has shown good safety characteristics in the completed Phase I clinical trials [1]

Group 1 - Zhonghui Biotech (02627) has successfully held the launch meeting for the Phase III clinical trial of its lyophilized human rabies vaccine (human diploid cells) in Hubei, marking a significant step towards successful commercialization of this core product [1] - Rabies is a zoonotic disease caused by the rabies virus (RABV), with a widespread geographical distribution affecting over 150 countries and regions, posing a severe threat to human life due to nearly 100% mortality once symptoms appear [1] - The onset of rabies symptoms is related to the speed at which the virus moves to the central nervous system, typically occurring 20 to 60 days post-infection, leading to acute encephalomyelitis and subsequent respiratory and circulatory failure [1] Group 2 - Currently, there is no effective treatment for rabies, making prevention crucial, with vaccination being the most effective control measure [2] - Human diploid cell rabies vaccine (HDCV) has a history of over 40 years of use in Europe and North America, with its safety and efficacy well-validated, recognized internationally as the "gold standard" for rabies vaccines [2] - The lyophilized human rabies vaccine (human diploid cells) has completed Phase I clinical trials, showing good safety profiles for both the Essen and Zagreb vaccination protocols in individuals aged 10 to 60 [2]

Group 1 - Zhonghui Biotech (02627) has successfully held the launch meeting for the Phase III clinical trial of its lyophilized human rabies vaccine (human diploid cells) in Hubei, marking a significant step towards successful commercialization of this core product [1] - Rabies is a highly infectious disease caused by the rabies virus (RABV), with a global presence in over 150 countries and regions, posing a severe threat to human life due to nearly 100% mortality once symptoms appear [2] - The human diploid cell rabies vaccine (HDCV) has a history of over 40 years of application in Europe and North America, with its safety and efficacy well-validated, recognized internationally as the "gold standard" for rabies vaccines [2]